Neurological effects of glucocerebrosidase gene mutations by Mullin, S et al.
Neurological effects of glucocerebrosidase gene mutations
S. Mullina,b, D. Hughesc, A. Mehtac and A. H. V. Schapiraa
aDepartment of Clinical Neuroscience, UCL Institute of Neurology, London; bInstitute of Translational and Stratified Medicine,
University of Plymouth School of Medicine, Plymouth; and cLSD Unit/Department of Haematology, Institute of Immunity and






Received 16 May 2018
Accepted 9 October 2018
European Journal of
Neurology 2018, 0: 1–9
doi:10.1111/ene.13837
The association between Gaucher disease (GD) and Parkinson disease (PD)
has been described for almost two decades. In the biallelic state (homozygous
or compound heterozygous) mutations in the glucocerebrosidase gene (GBA)
may cause GD, in which glucosylceramide, the sphingolipid substrate of the
glucocerebrosidase enzyme (GCase), accumulates in visceral organs leading to
a number of clinical phenotypes. In the biallelic or heterozygous state, GBA
mutations increase the risk for PD. Mutations of the GBA allele are the most
signiﬁcant genetic risk factor for idiopathic PD, found in 5%–20% of idio-
pathic PD cases depending on ethnicity. The neurological consequences of
GBA mutations are reviewed and the proposition that GBA mutations result
in a disparate but connected range of clinically and pathologically related
neurological features is discussed. The literature relating to the clinical,
biochemical and genetic basis of GBA PD, type 1 GD and neuronopathic
GD is considered highlighting commonalities and distinctions between
them. The evidence for a unifying disease mechanism is considered.
Introduction
Gaucher disease (GD) is an autosomal recessive disor-
der caused by mutations of the glucocerebrosidase
gene (GBA). The GBA encodes the lysosomal hydro-
lase glucocerebrosidase (GCase), which under acidic
conditions will hydrolyse the sphingolipid waste pro-
duct glucosylceramide into ceramide. Mutations cause
a reduction or complete loss of GCase activity which
(in the case of some biallelic subjects) leads to the
accumulation of glucosylceramide (and its deacylated
derivative glucosylsphingosine) in visceral organs,
causing a variety of clinical phenotypes. These include
thrombocytopaenia, anaemia, hepatosplenomegaly
and osteopaenia/osteonecrosis [1,2]. A subset of these
patients will also develop central nervous system
(CNS) features [1].
Gaucher disease is broadly categorized into three
subtypes. Type 1 GD (GD1) is diagnosed in the
absence of central neurological features, although
peripheral nervous system involvement in the form
of a symmetrical polyneuropathy does occur [3].
Type 2 GD (GD2) is characterized by rapid neuro-
logical deterioration and is ultimately fatal whilst in
type 3 GD (GD3) there are slower progressive neu-
rological features. In practice, the distinction
between GD2 and GD3 are often blurred and it
has been suggested that the exact neurological phe-
notype is more likely to be a spectrum disorder [4].
For the purpose of this review, types 2 and 3 will
be referred to collectively as neuronopathic Gaucher
disease (nGD).
The neurological phenotype of nGD
There is a substantial variation in the neurological
features associated with nGD. A supranuclear gaze
palsy is the most common clinical presentation; how-
ever, this may be because it is an easily identiﬁed clini-
cal feature which allows the diagnosis to be readily
made [1,4–6]. This advances the question whether in
fact the deﬁnition of nGD is an arbitrary waypoint in
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a spectrum of neurological features present across
nearly all Gaucher patients [7].
Otherwise cognition is the second most common
feature of nGD [5] in combination with a variety of
other features such as tremor, myoclonus, seizures,
gait disorders, bulbar dysfunction, stridor, muscle
weakness [1]. There appears to be some regional varia-
tion between this phenotype [3,8–10], which may or
may not be explained by variation in GBA mutations
present [11]. Equally, attempts to show mutation-spe-
ciﬁc phenotypes have been unsuccessful [4,7].
Central nervous system features in GD1
A minority of GD1 patients are known to develop
peripheral neuropathy [3]; however, the prevailing
view has been that GD1 patients do not develop cen-
tral nervous system (CNS) involvement. In recent
years, there have been grounds to consider the need
for revision of this view. The discovery that GD1
patients have a lifetime risk of developing Parkinson
disease (PD) of approximately 10%–30% compared
to approximately 1%–2% in the general population
indicates that CNS dysfunction as a consequence of a
GBA mutation can be lifelong. A study of the cogni-
tive proﬁle of Gaucher patients found that, compared
to age-matched controls, there was delayed recall of
verbal and non-verbal information along with reduced
attention [8].
Our own prospective data have shown general cog-
nitive impairment along with impaired olfaction
amongst not only GD1 patients but also ‘asymp-
tomatic’ heterozygous GBA carriers [12,13]. More-
over, deterioration of cognition, olfaction and
depression was more marked amongst both these
groups compared to controls. It is notable that the
distribution of these features correlates with the
sequence of prodromal symptoms that characterize
the preclinical phase of PD.
Glucocerebrosidase gene mutations and PD
Although a family history of idiopathic PD results in
approximately a fourfold increase in lifetime risk [14],
it is not ordinarily passed on in a Mendelian manner.
The recognition that GBA mutations are an impor-
tant risk factor for PD has proven to be an important
stimulus for additional insights into the pathogenesis
of PD. Unlike other genetic forms of PD, GBA muta-
tions display incomplete lifetime penetrance of around
10%–30% [3,4,7]. The GBA mutation minor allele
frequency is 1% in the general population [12,13], 5%
in the Ashkenazi population [3,15,16], between 5%
and 10% in idiopathic PD [8] and between 10%–30%
in Ashkenazi Jews with PD [3,15,16]. The precise fre-
quencies in the respective populations depend upon
whether the whole exome has been sequenced,
whether targeted microarray genotyping of speciﬁc
(common) mutations is carried out and upon the
inclusion or not of mutations such as E326K which is
not associated with Gaucher disease [12,13] but is
associated with an increased risk of PD [17].
The neurological phenotype of GBA PD
Although there is some debate about the GBA PD
phenotype, it appears to be associated with a more
pronounced cognitive deﬁcit. This is supported by
data which implicate GBA in dementia with Lewy
bodies, a form of dementia with associated parkinson-
ism and other diﬀerentiating features such as halluci-
nations [18]. Equally there are some data to suggest
that there is an enhanced neuropsychiatric phenotype.
Neuroanatomically, this has been considered to sug-
gest a more ubiquitous spread of Lewy pathology
across cortical brain regions, in contrast to PD which
predominantly aﬀects the basal ganglia, although
increasingly it is accepted that Lewy deposits aﬀect a
variety of brain regions, especially in late idiopathic
PD [19,20]. That said, asymmetrical reductions in
dopamine uptake have been demonstrated amongst
GBA PD subjects within the basal ganglia [21].
The clinical course of GBA PD has conclusively been
shown to be more aggressive, with a younger age of
onset compared to idiopathic PD and a lower median
survival time from diagnosis [22]. Some data indicate
that classical features of PD including asymmetrical
onset, bradykinesia, postural instability and rigidity are
less pronounced in GBA PD subjects [23]. To date, no
genetic association has been found with other synucle-
inopathies such as multisystem atrophy [3].
Mechanistic explanations for nGD and GBA
PD
There is no consensus on the underlying mode of
action of neurodegeneration in nGD and GBA PD. It
is beyond the scope of this paper to review these data
in detail; however, broadly they can be categorized
into those which postulate a loss of function and
those which postulate a gain of function. The argu-
ment of a loss of function centres primarily on the
ﬁnding of reduced GCase catalytic activity in both
GD (blood) and GBA PD [blood and cerebrospinal
ﬂuid (CSF)] [11,24,25]. However, there are major
inconsistencies in this argument. In particular, there is
a relatively poor correlation between GCase activity
levels and disease risk in PD and GD. For instance,
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one study showed that GCase activity from peripheral
blood spots categorized by mutation did not correlate
with the severity of those individual mutations in
terms of PD. L444P PD cases for instance appear to
have higher GCase activity than those with N370S,
even though L444P mutations convey between two
and three times the risk of PD compared to N370S
[11,26,27]. Equally, heterozygous carriers of the 84GG
mutation, which is a frameshift mutation and would
be expected to be null in terms of GCase activity, had
comparable enzyme activity with other missense GBA
mutations [28,29]. Although in GD residual GCase
activity has an inﬂuence, it does not in isolation pre-
dict disease prognosis [28]. A number of mechanisms
have been proposed by which loss of function could
lead to GD and PD. Predominantly, these are accu-
mulation of enzyme substrate (GD and PD) and fail-
ure of autophagic pathways leading to reduced
disposal of alpha synuclein [30].
It may be that this disparity is a reﬂection of the
limitations of the GCase activity assay. In leucocytes
GCase is typically normalized to the protein concen-
tration of the lysate produced and in CSF there is no
normalization to protein concentration at all [25,31].
Diﬀerences in the expression levels of the mutant and
wild-type GCase protein (from the remaining non-
mutated allele) will substantially inﬂuence what is
eﬀectively an assay that measures the rate of substrate
catalysis, yet to date there is no mechanism to nor-
malize for GCase protein expression.
Conversely, some argue that GBA induces a toxic
gain of function. Perhaps the most convincing of these
explanations comes from the work of Mia Horowitz
who suggests that sequestration of mutant GBA within
the endoplasmic reticulum, due to a failure of the nor-
mal process of post-translational folding, leads to a
variable degree of unfolded protein response which cor-
relates with the pathogenicity of the mutation [32].
There may of course be the potential for both loss
of function and a toxic gain of function to be coexis-
tent or perhaps more plausibly a product of one
another. For instance, any structural alteration to the
GCase protein may give rise to gain in function but
may incidentally reduce enzyme activity. Conversely, a
loss of enzyme activity may result downstream in an
added gain of function as a result of disruption of the
balance of substrate/product.
Neuropathology of GD and PD
Parkinson disease is pathologically well deﬁned by the
degeneration of the substantia nigra pars compacta
and the presence of Lewy bodies. These are protein
inclusions predominantly comprising alpha synuclein,
a ubiquitously expressed cytosolic protein of unknown
physiological function that appears to be central to
the pathological processes that contribute to PD
[33,34]. Its key importance is conﬁrmed by the ﬁnding
that missense mutations of the alpha synuclein gene
(SNCA) cause autosomal dominant familial PD
[24,25] whilst polymorphisms in SNCA cause a mar-
ginal protective/causative eﬀect in terms of developing
the PD phenotype [11]. Interestingly missense muta-
tions in the Rep1 promotor region [11,26,27] and
duplications/triplication of the whole SNCA gene
[28,29] are also implicated or causative of PD, with
the age of onset being proportional to the expression
levels of wild-type alpha synuclein protein. Lewy
pathology is present in around 20% of subjects of
over 80 years without any signs of parkinsonism, indi-
cating that alpha synuclein accumulates with age, a
process that reﬂects the age-related incidence of PD
[28].
A recent concept in the pathophysiology of PD is
that alpha synuclein may be transmitted in a prion-
like fashion [30]. Brieﬂy, alpha synuclein is a mono-
meric protein in the native state; however, under a
variety of intracellular conditions (such as proximity
to a lipid membrane [35] or oxidative stress [36]) it
converts to a beta sheet rich ﬁbrillar/oligomeric and
then an aggregated form [37]. It is this aggregated
phosphorylated form that is the major component of
Lewy bodies [38]. Postmortem examinations of PD
patients who received stem cell grafts as part of a clin-
ical trial showed that within a decade transplanted
neuronal tissue also contained Lewy pathology [39]. It
appears that aggregated alpha synuclein can ‘seed’
monomeric forms to adopt these ﬁbrillar/oligomeric/
aggregated conﬁgurations, which in turn can propa-
gate Lewy pathology to adjacent cells [40–43].
Some studies have demonstrated Lewy pathology in
the enteric nervous system [44–46] and have suggested
that it may propagate along peripheral nerves (most
prominently the vagus nerve), through the midbrain
and then subsequently into the cortex and neocortex,
with PD severity correlating with the extent of the
sequential spread of this pathology [47,48]. Concur-
rently, a series of prodromal features of PD sequen-
tially occur in a manner which is postulated to
correlate with the pathological spread [44,49,50].
Neuronopathic Gaucher disease has been less well
characterized. There are only a few postmortem stud-
ies of nGD patients, a substantial portion of which
were performed two to three decades ago [51–54].
There have also been a number of mouse models of
nGD, although most of these employ artiﬁcial disrup-
tion of the GBA gene to produce a broadly compara-
ble phenotype and are of questionable clinical
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relevance [55,56]. A common feature appears to be
microgliosis and subsequent astrogliosis and neuronal
loss, particularly in hippocampal regions [51,55], along
with substrate accumulation [52,54,55,57,58]. How-
ever, there appears to be signiﬁcant variation in the
severity of neuropathology in nGD cases, which is
broadly proportional to the degree of CNS involve-
ment [51]. A postmortem study of three GD1 patients
(all N370S homozygous or N370s compound
heterozygous) without clinical neurological involve-
ment revealed microgliosis and astrogliosis in cortical
and hippocampal regions [51]. This glial activation
mimics the distribution of hippocampal pathology in
nGD patients, with the distinction that amongst nGD
subjects there is accompanying neuronal loss [51].
Recent data suggest that the deacylated derivative
of glucosylceramide, glucosylsphingosine, may be the
pathogenic molecule in nGD. Most pertinently gluco-
sylsphingosine appears to be raised far more speciﬁ-
cally in (plasma) GD subjects than other biomarkers
including glucosylceramide [33,34]. Unfortunately,
only a few more recent studies have attempted to
quantify neuronal levels of the lipid; however, it
appears to be present in human nGD [54] and trans-
genic mouse brains [55].
Cell biology of GD and GBA PD
Glucocerebrosidase gene mutations may cause aber-
rant post-translational folding of the enzyme. This
prevents traﬃcking of the enzyme from the endoplas-
mic reticulum to the lysosome and causes the GCase
to become sequestered within the endoplasmic reticu-
lum [6,59,60]. The consequences of this are twofold.
On the one hand, insuﬃcient GCase reaches the lyso-
some to allow suﬃcient catalysis of glucosylceramide
to ceramide. The sequestered GCase also gives rise to
an unfolded protein response which in turn results in
oxidative stress in the cytosol [6,59–61].
In vitro studies have highlighted a bidirectional
inverse correlation between GCase activity and alpha
synuclein [62,63]. Concurrently, biophysical studies
have shown a direct interaction with alpha synuclein
which is lessened for GBA mutation carrying forms of
the enzyme [64,65]. These ﬁndings are within the
broader context of an established literature implicat-
ing diminished mechanisms of cellular autophagy in
idiopathic PD [66–68]. Interestingly, there appears to
be an age-dependent reduction in GCase activity in
both mice and human brain [69,70]. Moreover, GCase
activity levels are reduced compared to controls in the
brains of non-GBA idiopathic PD subjects [71]; how-
ever, studies looking at substrate accumulation are
somewhat varied. Some show no increase in
glucosylceramide or glucosylsphingosine levels in PD
or aged controls [72,73] but another found an increase
in the latter [69]. Mouse data have also shown age-
dependent upregulation of glucosylsphingosine and
two studies found that ceramide levels (the product of
substrate breakdown) are reduced in the brains of
GBA PD subjects [74,75]. Thus, although there is evi-
dence to support a role for GCase in the proteolysis
of alpha synuclein, with GBA mutations causing
reduced GCase activity and in turn reduced turnover
of cytosolic alpha synuclein, the precise mechanism
underlying this remains unknown.
Parallels between nGD and GBA PD
Variable penetrance of nGD and GBA PD
A particularly pertinent aspect of the natural history
of nGD and GBA PD is the variable penetrance of
the phenotype in both conditions (i.e. many with com-
patible genotypes will not develop PD, GD1 or nGD).
The mutation/phenotype correlation is not absolute,
although similar patterns exist across the two condi-
tions. For instance severe GBA mutations, which by
deﬁnition are associated with nGD [76], increase the
risk of PD by around four times compared to mild
ones [26]. Equally, speciﬁc mutations which are
known to be highly pathogenic in terms of nGD (such
as L444P) [77] are also amongst the most pathogenic
in terms of PD risk [78]. Conversely those which have
a questionable eﬀect on the GD phenotype [24,25],
such as E326K and T369M, deliver only a marginal
increase in PD risk [11].
Stratiﬁcation of disease risk by categorization of
mutations has aroused signiﬁcant interest in the con-
text of PD [11,26,27]. The severe/mild dichotomy has
been applied prospectively to PD cohorts, and it has
been shown to have a major impact on age at onset
of PD and median time to dementia [28,29]. It may
allow more eﬀective targeting of future disease modi-
fying treatments for PD, increase the power of clinical
trials of such compounds by allowing selection of sub-
jects who are likely to have a more rapid decline [28].
Moreover, the fact that the same mutations determine
the severity of neurological features in both GD and
PD suggests that a common mode of action is shared
by the two conditions.
Neuroinflammation in GBA PD and nGD
There is evidence for immune dysregulation associated
with, and putatively causative of, a number of the
major clinical phenotypes of GD [79–82]. Addition-
ally, there is substantial evidence of an increased risk
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of monoclonal gammopathy, multiple myeloma as
well as lymphoid malignancies within GD patients
[83,84]. GD patients have been shown to have
increased serum concentrations of interleukin 6 and
10 [79] whilst GBA knockout mice display upregula-
tion of a variety of immune markers and increased
levels of a variety of inﬂammatory cytokines in the
plasma [85,86]. This has been hypothesized to be a
result of accumulated glucosylceramide within the
mononuclear phagocytic system, although the precise
mechanism is still unclear [85].
Immune activation has also been highlighted as a
key factor in the pathogenesis of PD [87]. Substantial
in vitro data have directly linked alpha synuclein to
microglial activation, with a number of mechanisms
postulated [88–94]. This correlates with in vivo clinical
imaging studies [95], postmortem evidence [96,97],
serum titres of cytokines [98,99] and autoantibodies to
components of the synuclein aggregation pathway
[100]. Interestingly chronic use of non-steroidal anti-
inﬂammatory drugs has been shown to exhibit a
mildly protective eﬀect against PD onset [14]. One
study has also shown enhanced activation of a num-
ber of peripheral cytokines within GBA PD patients
[101].
Disease modifying therapy in GD, nGD and
GBA PD
Enzyme replacement therapy
The advent of recombinant enzyme replacement ther-
apy (ERT), given intravenously, usually on an
approximately monthly basis, has transformed the
prognosis for those with GD [2]; the majority of GD1
patients can now live practically normal lives. The
exception to this is nGD, which is at present unre-
sponsive to ERT as the 596 kDa protein is unable to
cross the blood–brain barrier [2,102]. There are vari-
ous strategies under consideration which aim to tem-
porarily permeabilize the blood–brain barrier to allow
recombinant ERT into the brain [103]. These include
use of a lentiviral vector to chaperone the protein
[104,105]. Intrathecal administration of ERT has been
used with some success in paediatric Hurler’s syn-
drome (mucopolysaccharidosis type 1) [106]. More-
over, a trial of intrathecal ERT in Hunter’s disease
(mucopolysaccharidosis type 2) is also under way
[107]. That said, there are a number of pitfalls which
must be overcome. The major challenge is ensuring
the ERT is able to breach the cell membrane and
reach the intracellular compartment. There is also the
very real danger of an immune mediated CNS inﬂam-
matory reaction following such administration [106].
Substrate reduction therapy
Other strategies to overcome the issue of CNS pene-
trance include substrate reduction therapy. Here inhi-
bition of upstream enzymes in the metabolic pathway
such as glucosylceramide synthase actively reduce sub-
strate production. Miglustat is one such compound.
Mouse models have shown, using microglial inﬂam-
mation as a surrogate marker of CNS penetrance,
that miglustat crosses the blood–brain barrier [108]
and there is some anecdotal evidence of clinical eﬃ-
cacy in GD3. However, a small randomized controlled
trial failed to prove this, although this may be on
account of the poor choice of primary outcome,
namely an improvement in supranuclear gaze palsy
[109,110]. Equally its use was associated with an
apparently increased incidence of peripheral neuropa-
thy [110,111].
In vitro studies have suggested that, in cell lines
expressing autosomal dominant alpha synuclein muta-
tions, these therapies reduce levels of the synuclein
protein [17], which has led to a phase II clinical trial
of the glucosylceramide synthase inhibitor venglustat
as a putative neuroprotective in GBA PD (clinicaltri-
als.gov, NCT02906020). Whilst intriguing, substrate
accumulation has not consistently been demonstrated
in PD brains. Nevertheless, it may be that minute
undetectable alterations in substrate levels interact
with alpha synuclein in other neurotoxic ways, such
as for instance by altering the aggregation dynamics
of the protein [112].
Small molecular chaperones
Another therapeutic strategy is the use of small molec-
ular chaperones which are also able to enter the CNS.
These compounds appear to modify the tertiary and
quaternary structure of GCase, facilitating post-trans-
lational folding and transport of GCase to the lyso-
some [113]. At the lysosome the change in pH causes
the chaperone to dissociate from GCase allowing
eﬀective catalysis to resume. A recent phase II trial of
ambroxol, a repurposed cough linctus which also acts
as a small molecular chaperone to GCase, showed
good CSF penetrance and a reduction of glucosylce-
ramide levels in the CSF [114]. Similarly our own
group is currently conducting a phase II trial of
ambroxol in PD patients (NCT02941822).
Gene therapy
Interest in gene therapy targeting the GBA gene up to
this point has been predominantly in the context of
GD [18]. Of particular interest has been the realistic
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prospect of such therapy crossing the blood–brain
barrier and hence being a viable treatment for neuro-
logical GBA related disease. Using invariant natural
T killer cells, it was shown in 2011 that Gaucher
ﬁbroblasts could be transfected using a high-titre,
amphotropic retroviral vector in which human GBA1
was driven by the mutant polyoma virus enhancer/
herpesvirus thymidine kinase gene promoter [19,20].
Unfortunately the clinical protocol that resulted
achieved a transfection eﬃciency of only 1%–10%
which was insuﬃcient to cause a clinically signiﬁcant
improvement in substrate levels [21]. Using a murine
GBA knockout model, an intravenously injected len-
tiviral vector was shown to be able to deliver
improved GCase activity, reduced substrate accumula-
tion and improvements in a number of clinical out-
comes [22]; however, whether such outcomes can be
replicated in human subjects is uncertain.
In the context of PD, moreover, it is unclear
whether aﬀected brain regions (e.g. the substantia
nigra and striatum) could be reached by such vector
technologies. However, systemic administration to
transgenic synuclein overexpressing mice of AAV9-
PHP.B (an AAV which readily crosses the blood–
brain barrier) resulted in complete clearance of alpha
synuclein throughout the brain [22]. The approach has
great promise as a means of readily crossing the
blood–brain barrier; however, ﬁnding stable and safe
means of eﬃcient transfection remains the principal
obstacle to its successful clinical application [23].
Concluding remarks
In this paper, it is suggested that in terms of CNS
involvement the traditional dichotomization of GD1
and nGD patients may require revision and that a
continuum of neurodegeneration may exist across
biallelic and heterozygous carriers of GBA mutations.
The evidence for this is mixed. The same (severe)
mutations are associated with a worse phenotype in
both diseases and the penetrance of this phenotype is
similarly variable. Neuropathologically, the presence
of substrate deposits in the brains of nGD patients
and their low or absent levels in heterozygous GBA
PD cases imply no commonality of pathology across
the two diseases. However, postmortem studies of
nGD and GD1 patients have identiﬁed a pattern of
microgliosis and then astrogliosis (with varying sever-
ity) which is anatomically very similar to that found
in dementia with Lewy bodies. In this spectrum GD2
and then GD3 patients represent the more severe neu-
rological phenotypes whilst GD1 patients and
heterozygous GBA carriers display variable degrees of
mild or subclinical neurological features. PD may
simply be another neurological phenotype caused by
GBA mutations.
No consensus exists regarding the pathogenic mech-
anism of nGD or GBA PD; however, a variety of
promising disease modifying strategies, targeting a
variety of proposed mechanisms, are currently in
development or under evaluation. The authors believe
that in the near future these approaches may elicit a
tangible disease modifying eﬀect in both diseases.
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